These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3296210)

  • 1. The alpha interferons: clinical overview.
    Spiegel RJ
    Semin Oncol; 1987 Jun; 14(2 Suppl 2):1-12. PubMed ID: 3296210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intron A (interferon alfa-2b): clinical overview and future directions.
    Spiegel RJ
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):89-101. PubMed ID: 3532338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha interferons: a clinical overview.
    Spiegel RJ
    Urology; 1989 Oct; 34(4 Suppl):75-9; discussion 87-96. PubMed ID: 2678686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-interferon in the treatment of nodular lymphomas.
    Urba WJ; Longo DL
    Semin Oncol; 1986 Dec; 13(4 Suppl 5):40-7. PubMed ID: 3541218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interferon-alpha in the treatment of hematologic neoplasms].
    Aulitzky W; Gastl G; Tilg H; Troppmair J; Leiter E; Geissler D; Flener R; Huber C
    Wien Med Wochenschr; 1986 Apr; 136(7-8):172-81. PubMed ID: 3524022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies.
    Steis RG; Smith JW; Urba WJ; Clark JW; Itri LM; Evans LM; Schoenberger C; Longo DL
    N Engl J Med; 1988 Jun; 318(22):1409-13. PubMed ID: 3367950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alfa interferon: combinations with other antineoplastic modalities.
    Bonnem EM
    Semin Oncol; 1987 Jun; 14(2 Suppl 2):48-60. PubMed ID: 3296212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia.
    Foon KA; Bunn PA
    Semin Oncol; 1986 Dec; 13(4 Suppl 5):35-9. PubMed ID: 3541217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotherapy with interferon--1988.
    Figlin RA
    Semin Oncol; 1988 Dec; 15(6 Suppl 6):3-9. PubMed ID: 2462749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interferon therapy in hematologic neoplasms].
    Schwarzinger I; Bettelheim P; Lechner K
    Wien Klin Wochenschr; 1988 Aug; 100(15):497-504. PubMed ID: 2459854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Various aspects and results of therapy with interferon].
    Niederle N
    Arzneimittelforschung; 1988 Mar; 38(3A):449-53. PubMed ID: 2456071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies.
    Tsimberidou AM; Giles F; Romaguera J; Duvic M; Kurzrock R
    Cancer; 2004 Feb; 100(3):574-80. PubMed ID: 14745875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I evaluation of a synthetic mutant of beta-interferon.
    Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
    Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon].
    Aulitzky W; Gastl G; Troppmair J; Tilg H; Abbrederis K; Nerl C; Flener R; Rokos H; Huber C
    Acta Med Austriaca; 1985; 12(5):115-21. PubMed ID: 3832745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant alpha interferons 1986: a review.
    Lindquist DL; Burns CP
    Iowa Med; 1987 Jan; 77(1):32, 34, 36. PubMed ID: 3818250
    [No Abstract]   [Full Text] [Related]  

  • 19. Biologic response modifiers: the interferon alfa experience.
    Koeller JM
    Am J Hosp Pharm; 1989 Nov; 46(11 Suppl 2):S11-5. PubMed ID: 2481396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha interferons in hairy cell leukaemia: a clinical model of biological therapy for cancer.
    Quesada JR
    Interferon; 1987; 8():111-34. PubMed ID: 3316039
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.